We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+35.36%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$3.5M
Cap. Flow
+$129M
Cap. Flow %
34.23%
Top 10 Hldgs %
57.24%
Holding
101
New
34
Increased
16
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$15.7M
2
ROIV icon
Roivant Sciences
ROIV
+$14.9M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
4
CABA icon
Cabaletta Bio
CABA
+$11.9M
5
IMVT icon
Immunovant
IMVT
+$11.1M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$11.8M
2
ACLX
Arcellx
ACLX
+$11M
3
MRUS
Merus
MRUS
+$10.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
5
MRK icon
Merck
MRK
+$9.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
51
CALL
DELISTED
Avidity Biosciences
RNAM
$184K 0.05%
+75,000
New +$1.18M
CRNX icon
52
PUT
Crinetics Pharmaceuticals
CRNX
$8.88B
$158K 0.04%
+175,000
New +$6.85M
ACLX
53
PUT
DELISTED
Arcellx
ACLX
$135K 0.04%
+50,000
New +$3.17M
BHVN icon
54
PUT
Biohaven
BHVN
$2.32B
$122K 0.03%
+30,000
New +$1.49M
FOLD
55
CALL
DELISTED
Amicus Therapeutics
FOLD
$120K 0.03%
+400,000
New +$5.12M
VERA icon
56
PUT
Vera Therapeutics
VERA
$2.76B
$75K 0.02%
+40,000
New +$1.43M
KRYS icon
57
PUT
Krystal Biotech
KRYS
$10.5B
$71K 0.02%
+20,000
New +$2.78M
AUTL
58
CALL
Autolus Therapeutics
AUTL
$383M
$68.8K 0.02%
+250,000
New +$1.56M
ROIV icon
59
PUT
Roivant Sciences
ROIV
$24.8B
$56.3K 0.01%
+750,000
New +$8.09M
TARS icon
60
PUT
Tarsus Pharmaceuticals
TARS
$2.61B
$41.3K 0.01%
+50,000
New +$1.47M
TARA icon
61
CALL
Protara Therapeutics
TARA
$230M
$13.2K ﹤0.01%
+87,900
New +$284K
UTHR icon
62
CALL
United Therapeutics
UTHR
$22.7B
$10.8K ﹤0.01%
+10,000
New +$2.26M
ACIU icon
63
AC Immune
ACIU
$224M
– –
-434,588
Closed -$2.17M
ACLX
64
CALL
DELISTED
Arcellx
ACLX
– –
-623
Closed -$283K
AMLX icon
65
Amylyx Pharmaceuticals
AMLX
$1.97B
– –
-83,381
Closed -$1.23M
ANIP icon
66
ANI Pharmaceuticals
ANIP
$1.8B
– –
-85,382
Closed -$4.71M
ARGX icon
67
CALL
argenx
ARGX
$53.8B
– –
-26,484
Closed -$10.1M
ARKG icon
68
PUT
ARK Genomic Revolution ETF
ARKG
$1.61B
– –
-5,000
Closed -$375K
ARWR icon
69
Arrowhead Research
ARWR
$10.5B
– –
-59,038
Closed -$1.81M
BBIO icon
70
BridgeBio Pharma
BBIO
$15.9B
– –
-253,948
Closed -$10.3M
CYTK icon
71
Cytokinetics
CYTK
$10.9B
– –
-24,111
Closed -$2.01M
ETNB
72
DELISTED
89bio
ETNB
– –
-408,257
Closed -$4.56M
EYPT icon
73
EyePoint Inc
EYPT
$1.12B
– –
-95,732
Closed -$2.21M
FATE icon
74
Fate Therapeutics
FATE
$324M
– –
-898,196
Closed -$3.36M
IBB icon
75
PUT
iShares Biotechnology ETF
IBB
$9.23B
– –
-2,000
Closed -$360K
1 2
3
4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Stempoint Capital held 101 positions worth $378M, up 0.93% from $375M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Stempoint Capital deployed $129M of net new capital in Q1 2024, opening 34 new positions and adding to 16 existing holdings. Its largest new stake was Tourmaline Bio: 274,219 shares worth $6.28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arcellx, an estimated $11M trimmed.

  • Stempoint Capital's largest Q1 2024 buy was Tourmaline Bio: 274,219 shares worth $6.28M.
  • Stempoint Capital added most to Autolus Therapeutics in Q1 2024, an estimated $15.7M increase.
  • Stempoint Capital's biggest Q1 2024 reduction was Arcellx, cutting an estimated $11M.
  • Stempoint Capital fully exited Protagonist Therapeutics in Q1 2024, selling an estimated $11.8M.
  • Stempoint Capital's ten largest holdings make up 57% of its $378M portfolio in Q1 2024.
  • Stempoint Capital opened 34 new positions and closed 39 in Q1 2024.
  • Stempoint Capital's portfolio value rose 0.93% quarter-over-quarter to $378M.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.